Sharp Clinical Officially Opens £9.5M Facility In Rhymney

Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, officially opened its new £9.5M facility in Rhymney at an Open House and ribbon-cutting ceremony recently.

Development of the site began in 2017 and following a successful inspection by the UK’s medicines regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA) in early 2019, the new facility is fully operational.

Investment in the state-of-the-art Clinical Services Centre of Excellence, which included £500,000 from the Welsh Government, means the company can offer an extended range of primary and secondary drug packaging, storage and distribution services from the site.

This milestone coincides with Sharp celebrating over thirty years in the delivery of clinical trial services in South Wales, which has secured over 70 skilled local jobs to the area with potential for more.

Ian Morgan, General Manager for Sharp Clinical Services UK, said:
“We are delighted to have officially ‘cut the ribbon’ on our brand-new clinical services facility in Rhymney. Investing in new facilities, increasing production capacity and expanding our capabilities helps us to meet growing demand for our services and is also an important way of creating jobs and supporting the communities where we operate.”

In designing the new facility, Sharp also demonstrated its commitment to the environment in which it operates, investing in a solar panel system which is already generating approximately 20% of its total annual electricity requirements.

“We have a long-standing history in the area and are dedicated to supporting both our customers and our employees for years to come and the investment in the Rhymney facility is a testament of that commitment.”

Sharp Clinical
Sharp Clinical offers a full complement of clinical trial services, including analytical, formulation development, clinical manufacturing and packaging, storage and distribution. Sharp also offers an interactive response technology (Clinical IRT) platform which can accommodate simple to complex randomization schemes as well as clinical supply chain management.

During 2018, Sharp Clinical invested $36M in new dedicated facilities in both the US and the UK and can offer QP services for European distribution. We service every phase of the drug lifecycle from Phase 1 through to commercialization and through our global network of over 30 depots we can distribute to every region of the world. Our highly experienced team will help you optimize every aspect of your clinical trial.

For more information on Sharp and its solutions, visit www.sharpservices.com.